Education in the Use of Biomarkers in Diabetes (C-EUBD)
Membership
Name | Position | Country | Term | Time in Office |
E. English | Chair | UK | 1st | 2021 04 - 2023 12 |
E. Van der Hagen | Member | NL | 1st | 2022 01 - 2024 12 |
A. Sato | Member | JP | 2nd | 2022 01 - 2024 12 |
J. Skrha | Member | CZ | 1st | 2022 01 - 2024 12 |
E. Kilpatrick | Member | UK | 1st | 2022 05 -2024 12 |
D. Sacks | Consultant | US | | |
E.Lenters-Westra | Consultant | NL | | |
C. Siebelder | Consultant | NL | | |
Terms of reference
- To maintain and further develop the network of reference laboratories for the measurement of HbA1c (through collaboration with C-TLM)
- To work in partnership with WHO and IDF to continue to promote the reporting of HbA1c in line with the consensus statement
- To work in partnership with WHO and IDF to facilitate the development and implementation of international guidelines for the use of HbA1c in the diagnosis of diabetes
- To work with IFCC Corporate Members to develop a consensus position on the information to be included in the Instructions for Use (IFU) as it relates to the clinical use of HbA1c methods
- Develop quality targets for the measurement of HbA1c and other biomarkers, and on the basis of these targets, and in conjunction with professional bodies, advise on the use of biomarkers for monitoring, diagnosis and screening of diabetes and glucose intolerance.
- To work with WHO and TF-POCT to recommend best practice in the use of POCT methods for the measurement of HbA1c
- To evaluate the clinical value of emerging biomarkers (e.g. glycated albumin) for the management of patients with diabetes and to establish whether there is a case for method harmonisation of effective new biomarkers
- To evaluate the emerging importance of post translational modification derived products (PTMDPs), and especially Advanced Glycation End-Products (AGEs), and work with Professional bodies on the best way of developing these for use in diabetes.
- To monitor the literature and advise on best practice in relation to laboratory aspects of diabetes.
List of Corresponding Members, nominated by National Societies
Name | IFCC Member Society |
D. Aslan | Turkish Biochemical Society (TBS) |
W. Cheneke Gebisa | Ethiopian Medical Laboratory Association (EMLA) |
E. Schleicher | Deutche Gesellschaft fur Klinische Chemie und Laboratoriumsmedizin e.V. (DGKL) |
A. Mosca | Italian Society of Clinical Chemistry and Clinical Molecular Biology (SIBioC) |
Iiris Salonen | Finnish Society of Clinical Chemistry (SKKY) |
A. Coj | Lithuanian Society of Laboratory Medicine |
E.Rojano-Rodriguez | Mexican Association of Clinical Laboratory Sciences (CMCLabC) |
R. Kumar Dubey | Nepalese Association for Clinical Chemistry (NACC) |
B. Kumar Yadav | Nepalese Association for Laboratory Science (NAMLS) |
B. Okesina | Association of Clinical Chemists Nigeria (ACCN) |
R. Nanda | Association of Medical Biochemists of India (AMBI) |
M. Banerjee | Association of Clinical Biochemists of India (ACBI) |
P. Gillery | Société Francaise de Biologie Clinique (SFBC) |
L. Figueroa Montes | Associacion Medica Peruana de Patologia Clinica (AMPPC) |
List of Corresponding Members, nominated by Corporate Members
Name | Company |
S. Baraldi | A. Menarini Diagnostics |
M. Berman | Abbott |
P. Campbell | LumiraDx |
R. Molinaro | Siemens Healthcare |
Committee Chair's contact
Prof. Emma ENGLISH
Associate Professor
School of Health Sciences,
University of East Anglia
Norwick Research Park,
Norwich, Norfolk
NR4 7TJ, UK
E-mail: Emma.English@uea.ac.uk